Compare Walt Disney Co (DIS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Pfizer Inc — how do they compare? Walt Disney Co trades at $107.09 (market cap $180.87B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Walt Disney Co and Pfizer Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Pfizer Inc for 158 Days on average.
| DIS | PFE | |
|---|---|---|
Market Cap | $180.87B | $159.59B |
Volume | 7,385,182 | 30,937,010 |
Sector | Media | Health |
52-Week High | $116.65 | $29.02 |
52-Week Low | $92.40 | $23.67 |
Typical Hold Time | 199 Days | 158 Days |
Enterprise Value | $221.73B | $211.09B |
Dividend Yield | 1.43% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.93% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $91.4B to $94.4B in 2025 and net income surging to $12.4B. Recent earnings beats and a $60B parks investment highlight strategic expansion. Analyst consensus remains strongly positive with a $125.67 price target, representing 17% upside potential from current levels.
Disney presents a compelling investment opportunity with accelerating profitability and strategic investments in experiences and streaming. Key risks include free cash flow pressure from elevated capital expenditures and competitive streaming landscape challenges. The stock's current valuation at 21.6x P/E appears reasonable given growth trajectory, though execution on content investments and margin expansion will be critical for sustained outperformance.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
